Published 1 day ago • loading... • Updated 15 hours ago

Bachelorette Katie Thurston cancels chemo just ‘minutes’ before first session

Summary by The US Sun

THE BACHELORETTE star Katie Thurston has cancelled her chemotherapy just ‘minutes’ before her first session after receiving a new diagnosis in her breast cancer battle. Katie, 34, recently revealed that her breast cancer has progressed to stage 4 after spreading to her liver. The Bachelorette star Katie Thurston has cancelled her chemotherapy just ‘minutes’ before her first sessionInstagram/thekatiethurston InstagramKatie recently revealed that …

6 Articles

All

Left

Center

Right

The US Sun

Right

Bachelorette Katie Thurston cancels chemo just ‘minutes’ before first session

21 hours ago

Read Full Article

Jingletree

Katie Thurston Thinks 'Chemo Is Off the Table for Now': Cancer Timeline

Katie Thurston was diagnosed with breast cancer in February 2025 at the age of 34. “I had a small lump in my breast around the 10’oclock [sic] spot,” the former Bachelorette wrote via her Instagram Stories that same month. “I discovered it myself. Thought maybe it was my period [or] maybe it was muscle soreness from working out. But, eventually, this lump never went away.” Thurston subsequently visited her doctor for a mammogram, which indicated…

15 hours ago

Read Full Article

pharmaceutical-technology.com

EC approves Daiichi and AstraZeneca’s Enhertu for breast cancer

The EC has approved Daiichi Sankyo and AstraZeneca’s Enhertu for use as a single agent to treat adults with certain breast cancers.

22 hours ago

Read Full Article

tipranks.com

Daiichi Sankyo, AstraZeneca’s Enhertu approved in European Union

Daiichi Sankyo (DSNKY) and AstraZeneca’s (AZN) Enhertu has been approved in the European Union as a monotherapy for the treatment of adult patients with unresectabl...

1 day ago

Read Full Article

Pharmaphorum

AZ grabs pair of EU approvals for top cancer drugs

AstraZeneca is celebrating two approvals for cancer drugs Imfinzi and Enhertu in the EU as it faces increased competition to its top-seller Tagrisso

1 day ago

Read Full Article

stocktitan.net

Breakthrough: ENHERTU Becomes First HER2 Treatment for Common Breast Cancer Type

Groundbreaking EU approval expands treatment options for 70% of breast cancer patients. Shows 38% reduced progression risk vs chemo. Full analysis inside.

1 day ago

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year